Table of Contents

1 Study Coverage

• 1.1 Retinal Drugs Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Retinal Drugs Market Size Growth Rate by Product
  • 1.4.2 Wet AMD
  • 1.4.3 Diabetic Retinopathy
  • 1.4.4 DME
  • 1.4.5 RVO
  • 1.4.6 Mcnv
• 1.5 Market by End User
  • 1.5.1 Global Retinal Drugs Market Size Growth Rate by End User
  • 1.5.2 Hospitial
  • 1.5.3 Clinicl
  • 1.5.4 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Retinal Drugs Market Size
  • 2.1.1 Global Retinal Drugs Revenue 2014-2025
  • 2.1.2 Global Retinal Drugs Sales 2014-2025
• 2.2 Retinal Drugs Growth Rate by Regions
  • 2.2.1 Global Retinal Drugs Sales by Regions
  • 2.2.2 Global Retinal Drugs Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Retinal Drugs Sales by Manufacturers
  • 3.1.1 Retinal Drugs Sales by Manufacturers
  • 3.1.2 Retinal Drugs Sales Market Share by Manufacturers
  • 3.1.3 Global Retinal Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Retinal Drugs Revenue by Manufacturers
  • 3.2.1 Retinal Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Retinal Drugs Revenue Share by Manufacturers (2014-2019)
• 3.3 Retinal Drugs Price by Manufacturers
• 3.4 Retinal Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Retinal Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Retinal Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Retinal Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Retinal Drugs Sales by Product
• 4.2 Global Retinal Drugs Revenue by Product
• 4.3 Retinal Drugs Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Retinal Drugs Breakdown Data by End User

6 North America

• 6.1 North America Retinal Drugs by Countries
  • 6.1.1 North America Retinal Drugs Sales by Countries
  • 6.1.2 North America Retinal Drugs Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Retinal Drugs by Product
• 6.3 North America Retinal Drugs by End User

7 Europe

• 7.1 Europe Retinal Drugs by Countries
  • 7.1.1 Europe Retinal Drugs Sales by Countries
  • 7.1.2 Europe Retinal Drugs Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Retinal Drugs by Product
• 7.3 Europe Retinal Drugs by End User

8 Asia Pacific

• 8.1 Asia Pacific Retinal Drugs by Countries
  • 8.1.1 Asia Pacific Retinal Drugs Sales by Countries
  • 8.1.2 Asia Pacific Retinal Drugs Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Retinal Drugs by Product
• 8.3 Asia Pacific Retinal Drugs by End User

9 Central & South America

• 9.1 Central & South America Retinal Drugs by Countries
  • 9.1.1 Central & South America Retinal Drugs Sales by Countries
  • 9.1.2 Central & South America Retinal Drugs Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Retinal Drugs by Product
• 9.3 Central & South America Retinal Drugs by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Retinal Drugs by Countries
  • 10.1.1 Middle East and Africa Retinal Drugs Sales by Countries
  • 10.1.2 Middle East and Africa Retinal Drugs Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Retinal Drugs by Product
• 10.3 Middle East and Africa Retinal Drugs by End User

11 Company Profiles

• 11.1 Bayer
  • 11.1.1 Bayer Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Bayer Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Bayer Retinal Drugs Products Offered
  • 11.1.5 Bayer Recent Development
• 11.2 F. Hoffmann-La Roche
  • 11.2.1 F. Hoffmann-La Roche Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 F. Hoffmann-La Roche Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 F. Hoffmann-La Roche Retinal Drugs Products Offered
  • 11.2.5 F. Hoffmann-La Roche Recent Development
• 11.3 Novartis
  • 11.3.1 Novartis Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Novartis Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Novartis Retinal Drugs Products Offered
  • 11.3.5 Novartis Recent Development
• 11.4 Regeneron
  • 11.4.1 Regeneron Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Regeneron Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Regeneron Retinal Drugs Products Offered
  • 11.4.5 Regeneron Recent Development
• 11.5 Merck
  • 11.5.1 Merck Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Merck Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Merck Retinal Drugs Products Offered
  • 11.5.5 Merck Recent Development
• 11.6 Shire
  • 11.6.1 Shire Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Shire Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Shire Retinal Drugs Products Offered
  • 11.6.5 Shire Recent Development
• 11.7 Teva Pharmaceutical
  • 11.7.1 Teva Pharmaceutical Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Teva Pharmaceutical Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Teva Pharmaceutical Retinal Drugs Products Offered
  • 11.7.5 Teva Pharmaceutical Recent Development
• 11.8 ThromboGenics
  • 11.8.1 ThromboGenics Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 ThromboGenics Retinal Drugs Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 ThromboGenics Retinal Drugs Products Offered
  • 11.8.5 ThromboGenics Recent Development

12 Future Forecast

• 12.1 Retinal Drugs Market Forecast by Regions
  • 12.1.1 Global Retinal Drugs Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Retinal Drugs Revenue Forecast by Regions 2019-2025
• 12.2 Retinal Drugs Market Forecast by Product
  • 12.2.1 Global Retinal Drugs Sales Forecast by Product 2019-2025
  • 12.2.2 Global Retinal Drugs Revenue Forecast by Product 2019-2025
• 12.3 Retinal Drugs Market Forecast by End User
• 12.4 North America Retinal Drugs Forecast
• 12.5 Europe Retinal Drugs Forecast
• 12.6 Asia Pacific Retinal Drugs Forecast
• 12.7 Central & South America Retinal Drugs Forecast
• 12.8 Middle East and Africa Retinal Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Retinal Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Retinal drugs are the medications that are used for the treatment of retinal diseases
North America dominated the global retinal drugs market in 2017
The global Retinal Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Retinal Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Retinal Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Retinal Drugs in these regions.
This research report categorizes the global Retinal Drugs market by top players/brands, region, type and end user. This report also studies the global Retinal Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Bayer
F. Hoffmann-La Roche
Novartis
Regeneron
Merck
Shire
Teva Pharmaceutical
ThromboGenics

Market size by Product
Wet AMD
Diabetic Retinopathy
DME
RVO
Mcnv
Market size by End User
Hospitial
Clinicl
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Retinal Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Retinal Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Retinal Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Retinal Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Retinal Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Retinal Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.